Christine Coyne's most recent trade in Iterum Therapeutics Plc was a trade of 200,000 Share Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iterum Therapeutics Plc | Christine Coyne | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 200,000 | 200,000 | - | - | Share Option (Right to Buy) | |
| Scynexis Inc | Christine Coyne | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Christine Coyne | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 43,200 | 58,200 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | Christine Coyne | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Christine Coyne | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock |